INCB054329
CAS No. 1628607-64-6
INCB054329( INCB 054329 )
Catalog No. M12432 CAS No. 1628607-64-6
INCB054329 is a novel potent, orally bioactive BET inhibitor that inhibits binding of BRD2, BRD3 and BRD4 to an acetylated histone H4 peptide with low nanomolar potency.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 140 | Get Quote |
|
| 10MG | 222 | Get Quote |
|
| 25MG | 447 | Get Quote |
|
| 50MG | 651 | Get Quote |
|
| 100MG | 888 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameINCB054329
-
NoteResearch use only, not for human use.
-
Brief DescriptionINCB054329 is a novel potent, orally bioactive BET inhibitor that inhibits binding of BRD2, BRD3 and BRD4 to an acetylated histone H4 peptide with low nanomolar potency.
-
DescriptionINCB054329 is a novel potent, orally bioactive BET inhibitor that inhibits binding of BRD2, BRD3 and BRD4 to an acetylated histone H4 peptide with low nanomolar potency; inhibits expression of c-MYC and induced HEXIM1 in myeloma cell lines; inhibits growth of the majority of myeloma, AML, and lymphoma cell lines with IC50<100 nM; induces G1 arrest and cell apoptosis consistent with increased expression of pro-apoptotic regulators; inhibits tumor growth in vivo.
-
In VitroINCB054329 is a bromodomain and extra-terminal motif (BET) inhibitor. INCB054329 inhibits binding of BRD2, BRD3 and BRD4 to an acetylated histone H4 peptide with low nanomolar potency. In myeloma cell lines, treatment with INCB054329 inhibits expression of c-MYC and induced HEXIM1. The majority of myeloma, AML, and lymphoma cell lines tested are growth inhibited by INCB054329 with potencies less than 200 nM. Selectivity is seen when compared with nontransformed cells as the potency for growth inhibition of IL-2 stimulated T-cells from normal donors is greater than 1300 nM. Cell cycle analysis reveals treatment-induced G1 arrest. Furthermore in both AML and lymphoma cell lines, INCB054329 induces apoptosis consistent with increased expression of pro-apoptotic regulators.
-
In VivoOral administration of INCB054329 inhibits tumor growth in several models of hematologic cancers. In the MM1.S multiple myeloma xenograft model, inhibition of tumor growth is correlated with reduction of c-MYC levels. PK-PD analysis shows c-MYC suppression is associated with an IC50 value of less than 100 nM in vivo.
-
SynonymsINCB 054329
-
PathwayChromatin/Epigenetic
-
TargetBromodomain
-
RecptorBromodomain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1628607-64-6
-
Formula Weight348.362
-
Molecular FormulaC19H16N4O3
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 100 mg/mL 287.06 mM
-
SMILESO=C1N2[C@H](COC3=C2C(N1)=CC=C3C4=C(ON=C4C)C)C5=CC=CC=N5
-
Chemical Name(S)-6-(3,5-dimethylisoxazol-4-yl)-3-(pyridin-2-yl)-3,4-dihydro-5-oxa-1,2a-diazaacenaphthylen-2(1H)-one
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Phillip CC Liu, et al. DOI: 10.1158/1538-7445.AM2015-3523 Published August 2015
2. Pérez-Salvia M, et al. Epigenetics. 2017 May 4;12(5):323-339.
molnova catalog
related products
-
AZD-5153
AZD-5153 is a potent, selective, bivalent and orally available BET/BRD4 bromodomain with IC50 of 5 nM.
-
GNE-207
GNE-207 (GNE207) is a novel potent, selective, orally active CBP/p300 bromodomain with IC50 of 1.0 nM.
-
CN750
CN750 (CN-750) is novel BRD4 (BD1, 2) inhibitor with IC50 of 44 nM, MV4-11 IC50 of 0.54 uM.
Cart
sales@molnova.com